GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • DuPont and Mylan are big market movers Monday, 27 Apr 2015 | 4:48 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. DuPont Co., up $3.29 to $74.81. Deutsche Bank AG, down $1.65 to $32.61.

  • REUTERS BUSINESS NEW SCHEDULE AT 1830 GMT/2:30 PM ET Monday, 27 Apr 2015 | 2:38 PM ET

    Apple Inc is expected to report a 20 percent increase in quarterly profit and that iPhone sales in China surpassed those in the United States for the first time., expect by 1930 GMT/ 4:30 PM ET, by Bill Rigby, 200 words). -BARRICK GOLD-RESULTS/, expect by expect by 1930 GMT/ 4:30 PM ET, 200 words). U.S. stocks move lower as healthcare stocks led by Amgen drag on the three major...

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed "high-risk" Teva stock. Mylan shares fell 5.7 percent to $71.71 on Nasdaq, and Teva fell 3.8 percent to $61.93 on the New York Stock...

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, saying it was too low and calling Teva stock an "unacceptable" currency. Mylan, which is pursuing its own takeover of Perrigo Co Plc, had been expected to reject the offer after having indicated that such a combination would not be a good fit.

  • REUTERS BUSINESS NEW SCHEDULE AT 1500 GMT/11 AM ET Monday, 27 Apr 2015 | 11:00 AM ET

    Editor: Alden Bentley +646 223 6200. Cap Gemini to buy U.S.-based IGATE for $4 bln, raises 2015 outlook. PARIS- Cap Gemini plans to buy United States- based IGATE Corp for $4 billion cash to make North America its biggest market and is raising its sales outlook for 2015 after a solid first-quarter, the French IT services company says.

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, but left the door open for talks. Mylan also said it remained committed to its offer for Perrigo Co Plc. Last week, Mylan said it would take its $31 billion offer for Perrigo directly to shareholders, in what is set to be one of the most high-profile...

  • Mylan rejects Teva's $40.1 billion buyout offer Monday, 27 Apr 2015 | 9:58 AM ET

    NEW YORK— Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company. Mylan is trying to buy Perrigo Co. of Ireland for about $30 billion in cash and stock, combining its own generic drug business with Perrigo's position in over-the-counter medications and other nonprescription...

  • Mylan rejects Teva's $40 bln offer Monday, 27 Apr 2015 | 9:31 AM ET

    April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer, saying it "grossly undervalues" the company.

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher on Friday, with the Nasdaq setting another record as investors cheered major earnings reports.

  • Mylan to submit formal offer for Perrigo Friday, 24 Apr 2015 | 11:39 AM ET
    Mylan headquarters in Canonsburg, Pa.

    Mylan announced Friday morning that it had commenced a formal offer to acquire Perrigo for a mix of cash and stock.

  • NEW YORK— Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan. Perrigo has already rejected Mylan's offer and reiterated Friday it feels the bid, worth more than $30 billion, is too low.

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • Mylan planning new offer for Perrigo: Source Wednesday, 22 Apr 2015 | 10:01 AM ET
    Tablets manufactured by Perrigo

    After its unsolicited takeover bid was denied, Mylan plans to make a new offer for Perrigo, according to a source familiar with the matter.

  • April 22- Teva Pharmaceutical Industries Ltd said on Wednesday it could "promptly" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV. Meanwhile, Canonsburg, Pennsylvania- based Mylan is pursuing its own $29 billion unsolicited bid for Perrigo Co Plc, which the maker of over-the-counter...

  • Teva's turnaround CEO sets sights on $40 bln mega-deal Wednesday, 22 Apr 2015 | 9:06 AM ET

    TEL AVIV, April 22- Israeli turnaround specialist Erez Vigodman, the chief executive of Teva Pharmaceutical Industries, is looking to pull off the ultimate transformation, with the biggest deal in Israel's corporate history. His unsolicited $40 billion offer for smaller generic drug rival Mylan Inc is Vigodman's attempt to turn Teva into a global drug...

  • FACTBOX-Teva Pharmaceutical's history of key acquisitions Wednesday, 22 Apr 2015 | 9:06 AM ET

    April 22- Teva Pharmaceutical Industries has offered to buy rival generic drugmaker Mylan for $40 billion in what would be the largest acquisition in Israel's history, equivalent to nearly 15 percent of GDP. *In March 2015 it said it would buy U.S. neurology drug company Auspex Pharmaceuticals for an equity value of $3.5 billion, a move to boost its portfolio of...

  • DUBLIN— Irish drug and over-the-counter ingredients maker Perrigo Co. said Tuesday it took a loss in its fiscal third quarter as it prepared to buy a Belgian competitor. Perrigo's fiscal third quarter ended on March 28, and the company closed its $4.48 billion purchase of Omega Pharma on March 30. Perrigo said Tuesday that that offer is too low because it doesn't...